Two leading researchers who have raised questions about the reliability of Sputnik V’s vaccine efficacy ratings across age groups shared their concerns with Health Policy Watch. One called the results “impossible” and “very concerning”. More than 70 countries have approved the use of Sputnik V, Russia’s COVID-19 vaccine, based on the reported 91.6% efficacy across […] Continue reading ->
The wider use of pooled procurement in national health systems can help low- and middle-income countries get a better deal on pharmaceuticals – here’s how and why. Low- and middle-income countries are making strides in bolstering their domestic pharmaceutical sectors—evidenced by the recent deal between South Africa’s Afrigen Biologics and Belgium’s Univercells, to develop the […] Continue reading ->
Pfizer and BioNTech have announced positive safety, tolerability and immunogenicity data for two Omicron-adapted COVID-19 mRNA candidate vaccines – but for an earlier strain of Omicron than those that are currently globally dominant.  The two Omicron-adapted vaccine candidates were given to 1,234 participants aged 56 years and older as boosters, and “elicited substantially higher neutralizing […] Continue reading ->
Children infected with COVID-19 maintained strong immunity against the virus for at least 18 months, according to a preprint study that was released on Wednesday. The study, which has not yet been peer-reviewed, was conducted by Kahn-Sagol-Maccabi (KSM), the research and innovation center of Maccabi Healthcare Services in Israel, and was released on the preprint server […] Continue reading ->
One year since the establishment of the mRNA Vaccine Technology Transfer Hub, a collaboration between two leading biotech companies – Afrigen Biologics and the Univercells group – was announced on Tuesday, paving the way for the development of the first-ever African-owned COVID-19 vaccine through open-access intellectual property.  Using intellectual property from partners, the collaboration between […] Continue reading ->